Based on clinical practice, it could be predicted that, as mentioned earlier, the group of HR+/HER2− patients in both local, advanced, or metastatic cancer would be the most suitable for receiving the combination therapies detailed in Table 4. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm.